Atherosclerosis in psoriatic arthritis: A multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function

International Journal of Angiology

Volumn 25, Issue 4, 2016, Pages 222-228

  Garg, Nidhi ^a   Krishan, Pawan ^a   Syngle, Ashit ^b  

^a PUNJABI UNIVERSITY   (India)

^b Fortis Multi Specialty Hospital   (India)

Author keywords

adhesion molecules; atherosclerosis; carotid intima media thickness; endothelial dysfunction; endothelial progenitor cells; inflammatory cytokines; psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LIPID; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY SCORE; DISEASE MARKER; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL PROGENITOR CELL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; GENDER; HUMAN; IMAGING; INFLAMMATION; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS;

EID: 84976865366     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0036-1584918     Document Type: Article

References (38)

1. Gladman D. D., Antoni C., Mease P., Clegg D. O., Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis: 2005; 64 02 ii14 ii17
2. Wong K., Gladman D. D., Husted J., Long J. A., Farewell V. T. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum: 1997; 40 10 1868 1872
3. Peters M. J., van der Horst-Bruinsma I. E., Dijkmans B. A., Nurmohamed M. T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum: 2004; 34 3 585 592
4. Kölliker Frers R. A., Bisoendial R. J., Montoya S. F., et al. Psoriasis and cardiovascular risk: Immune-mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metab Endocr: 2015; 6 43 54
5. Kimhi O., Caspi D., Bornstein N. M., et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum: 2007; 36 4 203 209
6. Di Minno M. ND, Ambrosino P., Lupoli R., et al. Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies. Ann Med: 2015; 47 4 346 353
7. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum: 2006; 54 8 2665 2673
8. Huang K., Zou C. C., Yang X. Z., Chen X. Q., Liang L. Carotid intima-media thickness and serum endothelial marker levels in obese children with metabolic syndrome. Arch Pediatr Adolesc Med: 2010; 164 9 846 851
9. Garg N., Krishan P., Syngle A. Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis. Clin Rheumatol: 2015; 34 6 1065 1071
10. Allanore Y., Batteux F., Avouac J., Assous N., Weill B., Kahan A. Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol: 2007; 25 1 60 66
11. Herbrig K., Haensel S., Oelschlaegel U., Pistrosch F., Foerster S., Passauer J. Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis: 2006; 65 2 157 163
12. Gonzalez-Juanatey C., Llorca J., Amigo-Diaz E., Dierssen T., Martin J., Gonzalez-Gay M. A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum: 2007; 57 6 1074 1080
13. Gonzalez-Juanatey C., Llorca J., Testa A., Revuelta J., Garcia-Porrua C., Gonzalez-Gay M. A. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore): 2003; 82 6 407 413
14. Salmon J. E., Roman M. J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med: 2008; 121 10 01 S3 S8
15. Verma I., Krishan P., Syngle A. Predictors of Atherosclerosis in Ankylosing Spondylitis. Rheumatol Ther: 2015; 2 173 182
16. Puato M., Ramonda R., Doria A., et al. Impact of hypertension on vascular remodeling in patients with psoriatic arthritis. J Hum Hypertens: 2014; 28 2 105 110
17. Eder L., Zisman D., Barzilai M., et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol: 2008; 35 5 877 882
18. Bots M. L., Grobbee D. E. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther: 2002; 16 4 341 351
19. Atzeni F., Sarzi-Puttini P., Sitia S., et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol: 2011; 38 8 1661 1664
20. Magro-Checa C., Orgaz-Molina J., Rosales-Alexander J. L., et al. Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls. Ann Rheum Dis: 2013; 71 572
21. Grisar J., Aletaha D., Steiner C. W., et al. Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation: 2005; 111 2 204 211
22. Del Papa N., Quirici N., Soligo D., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum: 2006; 54 8 2605 2615
23. Verma I., Syngle A., Krishan P. Endothelial dysfunction in ankylosing spondylitis associated with reduced endothelial progenitor cell population. IJRCI: 2015; 3 1 OA3
24. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res: 2001; 89 1 E1 E7
25. Schmidt-Lucke C., Rössig L., Fichtlscherer S., et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation: 2005; 111 22 2981 2987
26. Gonzalez-Juanatey C., Llorca J., Miranda-Filloy J. A., et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum: 2007; 57 2 287 293
27. Altekin E. R., Koç S., KarakaŚ M. S., et al. Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis. Turk Kardiyol Dern Ars: 2012; 40 7 574 580
28. Verma S., Wang C. H., Li S. H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation: 2002; 106 8 913 919
29. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med: 1999; 340 6 448 454
30. Alenius G. M., Eriksson C., Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol: 2009; 27 1 120 123
31. Sattar N., McCarey D. W., Capell H., McInnes I. B. Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation: 2003; 108 24 2957 2963
32. Sattar N., Crompton P., Cherry L., Kane D., Lowe G., McInnes I. B. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum: 2007; 56 3 831 839
33. Hughes M., Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford): 2013; 52 9 1728 1729
34. Riccieri V., Spadaro A., Taccari E., et al. Adhesion molecule expression in the synovial membrane of psoriatic arthritis. Ann Rheum Dis: 2002; 61 6 569 570
35. Poston R. N., Haskard D. O., Coucher J. R., Gall N. P., Johnson-Tidey R. R. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol: 1992; 140 3 665 673
36. Dessein P. H., Joffe B. I., Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther: 2005; 7 3 R634 R643
37. Rho Y. H., Chung C. P., Oeser A., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum: 2009; 61 11 1580 1585
38. Tam L. S., Tomlinson B., Chu T. T., et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology (Oxford): 2008; 47 5 718 723